The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 6 constituents from our Pure-Play Marijuana Drug Stocks Index sub-category and 12 from our Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which index has done the best so far in December? Which constituents contributed to their performances? How to they compare YTD? This article has the answers.

One hundred clinical-stage psychedelic drug stocks now trade on North American stock exchanges. Sixty of them (see here) research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know). The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $35M (only eight have market caps below $100M) and only 18 of those 100 psychedelic drug stocks meet that criteria.

The performance of the constituents in both indices month-to-date are presented below with the year-to-date (YTD) performance of each in brackets:

The 6 constituents in the Pure-Play Marijuana Drug Stocks Index have hyperlinks to 3 areas of additional information which are imperative for any individual considering investing in this sector:

• The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
• The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
• The percentage increase YTD is hyperlinked to a chart of the company's stock performance YTD.
• The "financial distress" percentage is sourced from macroaxis.com (visit the site and type in the stock symbol to obtain detailed financial data on the health of the company).

The Pure-Play Marijuana Drug Stocks Index

The 6 marijuana-based clinical-stage stocks:

• are DOWN -13.8% so far in December, 
• are now DOWN -29.5% YTD,
• of which 3 are trading below $1/share; another 2 trading for less than $2/share  and 1 trading for $3.23/share with an average price of $1.20/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) and
• with an average market capitalization of $90M currently.

1. Allied Corp. (ALID): DOWN -2.8% MTD (UP +134.7% YTD)
   • engaged in the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder
   • has about a 24% chance of experiencing some form of financial distress in the next two years of operation
2. Zynerba (ZYNE): DOWN -10.3% MTD (DOWN -2.1% YTD)
   • operates as a clinical stage specialty pharmaceutical company
   • has more than a 55% chance of experiencing financial distress in the next 2 years of operation
3. Revive (RVVTF): DOWN -15.4% MTD (DOWN -32.7% YTD)
   • focuses on the research and development of therapeutics for rare disorders and infectious diseases
   • has a very small chance of experiencing financial distress in the next few years
4. Corbus (CRBP): DOWN -20.5% MTD (DOWN -44.0% YTD)
   • focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer
   • has a greater than 89% chance of experiencing financial distress in the next few years of operation
5. Enveric (ENVB): DOWN -26.2% MTD (DOWN -74.9% YTD; yes, -74.9% YTD)
   • developing cannabinoid medicines for cancer care such as radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy
   • has over a 58% chance of experiencing financial distress in the next 2 years of operation
6. Tetra Bio (TBPMF): DOWN -33.3% MTD (DOWN -33.3% YTD)
   • engages in the discovery and development of immunomodulator drugs including PPP003 for painful dry eye and uveitis pain and HCC011 for hepatocellular carcinoma
   • has about a 28% chance of experiencing financial distress in the next 2 years of operation

The Pure-Play Psychedelic Compounds-Based Drug Stocks Index

The 12 psychedelic compound-based clinical-stage stocks are divided into 2 groups based on their market capitalizations.

The 9 constituents with market caps below $1B:

• are DOWN -19.0% so far in December,
• are now DOWN -26.5% YTD
• with 4 trading below $1/share; another 3 trading for less than $2/share, and 2 trading between $2 and $3/share with an overall average price of $1.43/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) with
• an average market capitalization of $171M.

1. Red Light (TRUFF) Unchanged in price MTD (now DOWN -52.0% YTD)
   • plans to produce, market, and distribute a premium health and wellness brand of psilocybin truffles within the Netherlands.
   • has less about a 25% chance of experiencing financial distress in the next few years of operation.
2. Cybin (CYBN): DOWN -6.7% MTD (DOWN -16.0% YTD)
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
   • has over a 62% chance of experiencing financial distress in the next few years of operation.
3. Seelos (SEEL): DOWN -7.6% MTD (still UP +8.2% YTD)
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
   • has over a 74% chance of experiencing financial distress in the next few years of operation.
4. Awakn (AWKNF): DOWN -8.4% MTD (DOWN -5.0% since launch on June 23rd) Read: Awakn Life Sciences: Wake Up To The Huge Potential
   • engaged in researching and developing psychedelic drugs focuses to treat addiction as well as delivering psychedelic treatments for addiction in clinics in the UK and EU.
   • has a 50% chance of experiencing financial distress in the next 2 years of operation.
5. Small Pharma (DMTTF): DOWN -15.6% MTD ( now DOWN -25.0% since launch in June, 2021)
   • focused on developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.
   • has over a 77% chance of experiencing some form of financial distress in the next two years of operation
6. Mind Medicine (MNMD): DOWN -16.3% MTD (now DOWN -44.6% YTD),
   • focused on the development of a pipeline of treatments to address addiction and mental illness based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
   • has over a 58% chance of experiencing financial distress in the next few years of operation.
7. Numinus (NUMIF): DOWN -24.1% MTD (now DOWN -47.6% YTD)
   • provides clients with testing of controlled compounds such as LSD, ketamine, DMT, MDMA, mescaline, psilocybin and psilocin as well as conducting research of both MDMA and psilocybin to treat PTSD, depression, anxiety, and addiction.
   • has over a 77% chance of experiencing financial distress in the next few years of operation.
8. Mydecine (MYCOF): DOWN -31.3% MTD (now DOWN -68.6% YTD; yes, -68.6% YTD!)
   • focused on clinical trials focusing on veterans, EMS, and first responders with a PTSD indication.
   • has about a 24% chance of experiencing some form of financial distress in the next two years of operation.
9. Field Trip (FTRP): DOWN -36.7% MTD (now DOWN -19.4% YTD)
   • focused on building centers for psychedelic therapies across North America and Europe.
   • has about a 27% chance of experiencing some form of financial distress in the next two years of operation.

The 3 constituents with market caps above $1B:

• are DOWN -16.5% so far in December,
• are now DOWN -27.9% since the end of June
• with one trading at $7.72/share; another trading at $23.71/share and the other trading at $23.78/share with an average price of $18.40/share (Currency amounts are in U.S. dollars. Go here to convert to another currency) with
• an average market capitalization of $1.1B

1. GH Resources (GHRS): UP +6.8% MTD (now UP +23.2% since the end of June)
2. Atai (ATAI): DOWN -31.0% MTD (now DOWN -57.2% since the end of June)
3. Compass Pathways (CMPS): DOWN -27.4% MTD (and now DOWN -36.2% since the end of June)

On average, the 12 constituents in the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index:

• are DOWN -16.9% so far in December
• are now DOWN -30.6% since the end of June
• and now have an average market capitalization of $411M.

In Summary

In answer to the opening question as to which Index is doing the best so far in December:

• the munKNEE Pure-Play Marijuana Drug Stocks Index is DOWN -13.8% month-to-date and is now DOWN -29.5% YTD,
• the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index is DOWN -19.0% month-to-date and is now DOWN -26.5% since the end of June and
• the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index of all 18 constituents is DOWN -16.6% month-to-date and is now DOWN -31.1% since the end of June.

As a point of comparison, the non-tradable Psychedelic Invest Index, of ALL 60 psychedelic clinical-stage drug stocks in the sector (an average market capitalization of just $120M) is DOWN -17.6% since the end of November while the non-tradable Psychedelic Market Leaders Index, which tracks the 30 largest market cap clinical-stage psychedelic stocks in the sector (an average market cap of $220M) is down -17.3% MTD so both of these indices closely match the performance of the 18 constituents in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index.